Where does Esperance Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Esperance Pharmaceuticals, Inc. ranks #35,229 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Esperance Pharmaceuticals, Inc. hold?

Esperance Pharmaceuticals, Inc. holds 7 US utility patents granted between 2016 and 2021, spanning 5 technology areas.

What is Esperance Pharmaceuticals, Inc.'s Innovation Score?

Esperance Pharmaceuticals, Inc. has an Innovation Score of 30.1 out of 100 (33rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Esperance Pharmaceuticals, Inc. focus on?

Esperance Pharmaceuticals, Inc.'s top technology area is C07K (Peptides) with 7 patents. Grants appear in 5 CPC subclasses total.

Is Esperance Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Esperance Pharmaceuticals, Inc.'s recent grant velocity is -60% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Esperance Pharmaceuticals, Inc.'s patents?

Esperance Pharmaceuticals, Inc.'s patents average 26.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Esperance Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Esperance Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2016–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Esperance ranks #35,229 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#35,229
of 49,997 US assignees by volume: 33rd percentile
by Innovation Score (30.1/100): 26.3
avg claims per patent: -60%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35229 · US Corporation #35,229 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #35,229/49,997
PHOTO-FINISH Eptech
CPC-NARROW C07K · 5 areas
INNOV-THIN 30.1/100
CLAIMS-DENSE 26.3 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -60% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Eptech Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Esperance Pharmaceut… · this assignee

30
3D Lighting… · lowest

7

What this shows Esperance's Innovation Score is 30.1/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Esperance's grants concentrate

Esperance Pharmaceuticals, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2017. By volume, Esperance sits between Eptech Co., Ltd. and Etablissements Pierre Grehal ET CIE S.A..

Eptech

7
Equalia

7
Eskom Holdings SOC

7
ESM Energie—UND S…

7
Essa Pharma

7
Essencore

7
Estar

7
Etablissements Pi…

7
Esperance Pharmac… ◀

7

What this shows Esperance holds 7 patents at rank #35,161, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Esperance

By rank, the assignees closest to #35,161 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Esperance's primary technology class.

Esperance's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Esperance Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	28.6%
2017	1	14.3%
2018	1	14.3%
2019	1	14.3%
2020	1	14.3%
2021	1	14.3%

Which technologies does Esperance Pharmaceuticals, Inc. patent most?

C07K - Peptides 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#35,229

of 49,997 tracked assignees

Innovation Score

30.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Esperance Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Esperance Pharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #35,229 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Esperance Pharmaceuticals, Inc. against Eptech Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.